Last reviewed · How we verify
NCT05368467: NCPVD
National Registry and Cohort Study of Pulmonary Vascular Disease
trial testing The clinical course and disease management in Pulmonary Arterial Hypertension in 1,000 participants. Currently enrolling.
30 December 2028
Quick facts
| Lead sponsor | Nanjing First Hospital, Nanjing Medical University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 29 March 2022 |
| Primary completion | 30 December 2028 |
| Estimated completion | 30 December 2028 |
| Sites | 13 locations across China |
Drugs / interventions tested
- The clinical course and disease management
Conditions studied
- Pulmonary Arterial Hypertension — all drugs for Pulmonary Arterial Hypertension →
Sponsor
Nanjing First Hospital, Nanjing Medical University
Who can join
Eligibility, any sex, with Pulmonary Arterial Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a observational、multicenter, prospective cohort study for patients with pulmonary hypertension (PH). The purposes of this study were to evaluate the etiology、clinical characteristics、treatment modalities, and outcomes of patients with PH；also to set up registration system of PH in China, to build a database of Chinese PH, to establish a web-based international standard data acquisition system for PH and a multicenter clinical research platform. The results of the study will provide a basis for the future national health policy for prevention and treatment of PH.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Substance P Promotes Pulmonary Hypertension by Inducing Fibulin-2 Methylation to Regulate β-Catenin.
Yi W, Minghui Z, Le Z, Yingying W, et al · · 2025 · PMID 41250681 · DOI 10.1002/pul2.70196
Verify or expand the search:
- PubMed search for NCT05368467
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pulmonary Arterial Hypertension
Currently open trials in the same condition.
- NCT07391228 — Cognitive Alterations in Pulmonary Arterial Hypertension (PAH) · active not recruiting
- NCT06351345 — 129 Xenon Imaging in Patients Treated With Sotatercept · Phase 2 · recruiting
- NCT07217522 — Rutgers University Study of the Genetics of Pulmonary Hypertension · recruiting
- NCT07013149 — The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension · recruiting
- NCT06658522 — Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effec · Phase 4 · recruiting
Other Nanjing First Hospital, Nanjing Medical University trials
Trials by the same sponsor.
- NCT07349979 — PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy · NA · not yet recruiting
- NCT07505056 — Jianpi Lishi Jiedu Granules for Prevention of Postoperative Recurrence in Colorectal Advanced Adenomas · Phase 3 · not yet recruiting
- NCT07397234 — Thyroid Cartilage Plane VS Superior Laryngeal Nerve Space Block in Awake Tracheal Intubation · NA · not yet recruiting
- NCT07455448 — Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study · completed
- NCT07385885 — Ultrasound-guided Non-invasive Simulation in Anesthesia Residency Training · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05368467 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanjing First Hospital, Nanjing Medical University
- Last refreshed: 26 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05368467.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing